TY - JOUR T1 - Improving care of melanoma patients through efficient, integrated cellular-molecular pathology workflows using tissue samples with low tumour nuclear content JF - Journal of Clinical Pathology JO - J Clin Pathol DO - 10.1136/jclinpath-2022-208194 SP - jclinpath-2022-208194 AU - Alison Finall AU - Kate Murphy AU - Ricky Dylan Frazer Y1 - 2022/04/15 UR - http://jcp.bmj.com/content/early/2022/04/14/jclinpath-2022-208194.abstract N2 - Aims The aim of this quality improvement project was to improve the turnaround time of B-raf proto-oncogene (BRAF) mutation testing in patients with malignant melanoma to support oncologists in making timely treatment decisions.Methods This is a prospective in-house verification of the Idylla BRAF test as compared with DNA panel next-generation sequencing (NGS) performed at an external laboratory.Results The Idylla BRAF test had an overall concordance of 95% compared with NGS. This was considered sufficiently good for use in patients with a poor performance status who were at risk of rapid clinical deterioration. Reliable results can be generated using the Idylla BRAF test in tissue sections with tumour neoplastic cell content below 50%. We present a multidisciplinary clinical care algorithm to support dual testing.Conclusions The Idylla BRAF test has the potential to make a significant positive impact on progression-free survival of malignant melanoma patients due to its rapid turnaround time. The Idylla BRAF test can be used as an adjunct to NGS for timely management of patients, particularly those with a poor performance status at presentation.Data are available on reasonable request. ER -